Table 3 Prevalence of major adverse cardiovascular events and all-cause mortality and electrocardiographic parameters according to fatty acid-binding protein 4 level
Parameter | First tertile | Second tertile | Third tertile | P for trend |
|---|---|---|---|---|
FABP4 (ng/mL) | ≤7.4 | 7.5–16.25 | > 16.25 |  |
Number | 132 | 133 | 132 | Â |
LVEF (%) | 62.7 ± 11.5 | 62.9 ± 11.1 | 57.9 ± 12.8 | 0.001 |
Hs-CRP (mg/L) | 1.3 (0.4–4.6) | 1.8 (0.7–4.0) | 4.4 (1.5–10.1) | 0.043 |
White blood cell count (×109/L) | 8.212 ± 2.991 | 8.011 ± 3.322 | 9.188 ± 4.058 | 0.356 |
ECG parameters | ||||
 Heart Rate (bpm) | 72.0 ± 16.8 | 74.1 ± 16.2 | 82.4 ± 16.6 | 0.001 |
 PR interval (ms) | 168.2 ± 34.0 | 166.4 ± 33.6 | 172.7 ± 32.4 | 0.812 |
 QRS duration (ms) | 95.1 ± 13.4 | 96.0 ± 18.9 | 99.5 ± 19.9 | 0.020 |
 QT interval (ms) | 403.1 ± 39.5 | 402.1 ± 38.2 | 399.9 ± 45.0 | 0.743 |
 QTc interval (ms) | 436.0 ± 30.7 | 440.2 ± 34.4 | 461.5 ± 39.2 | < 0.0001 |
Medication (n, %) | ||||
 Anti-arrhythmic medication | 34 (25.8) | 38 (28.6) | 41 (31.1) | 0.634 |
 Beta-blockers | 22 (16.7) | 23 (17.3) | 23 (17.4) | 0.985 |
 Diuretics | 12 (9.1) | 6 (4.5) | 10 (7.6) | 0.333 |
 Statins | 38 (28.8) | 36 (27.1) | 33 (25.0) | 0.786 |
Hypertension (n, %) | 77 (58.3) | 99 (74.4) | 109 (82.6) | < 0.0001 |
Dyslipidemia (n, %) | 84 (63.6) | 92 (69.2) | 83 (62.9) | 0.501 |
Diabetes (n, %) | 31 (23.5) | 53 (39.9) | 82 (62.1) | < 0.0001 |
Heart failure (n, %) | 14 (10.6) | 15 (11.3) | 36 (27.3) | 0.0002 |
Chronic kidney diseasea (n, %) | 36 (27.3) | 58 (43.6) | 105 (79.6) | < 0.0001 |
MACEs (n, %) | 41 (31.1) | 47 (35.3) | 66 (50.0) | 0.004 |
All-cause Mortality (n, %) | 1 (0.8) | 4 (3.0) | 9 (6.8) | 0.026 |
Non-fatal outcome (n, %) | ||||
 Heart failure | 6 (4.6) | 6 (4.5) | 15 (11.4) | 0.028 |
 Target lesion revascularization | 28 (21.2) | 32 (24.1) | 31 (23.5) | 0.562 |
 Recurrent myocardial Infarction | 6 (4.6) | 5 (3.8) | 11 (8.3) | 0.180 |